Business Wire

LANDSVIRKJUN

11.4.2022 20:02:06 CEST | Business Wire | Press release

Share
PCC SE and Landsvirkjun to Turn Emissions into Green Methanol to Decarbonize Transport

Landsvirkjun, The National Power Company of Iceland, and German investment company PCC SE have agreed to jointly explore the possibility of capturing and utilizing carbon emissions from PCC’s silicon metal plant in northeast Iceland. Carbon emissions will be utilized to produce green methanol that can for example replace fossil fuel in ships.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005136/en/

Green methanol will play a role in mitigating climate change

Methanol is not only a liquid chemical used in thousands of products of daily use, but green methanol is seen by many as a promising alternative energy carrier to fossil fuels and has the potential to play a key role in decarbonizing shipping vessels. The production of green methanol requires a renewable carbon source from PCC’s silicon metal plant in Iceland and renewable power from Landsvirkjun´s power stations. The process of methanol synthesis requires the input of pure carbon dioxide and hydrogen from water electrolysis, with the only by-product being oxygen and water. Turning carbon dioxide from waste into a valuable resource by utilizing and producing fuel for industries will help mitigate climate change and the transition to a circular economy.

Silicon metals used in innovative solutions for energy transition

PCC SE aims for their silicon metal plant at Húsavík to become carbon neutral by replacing fossil carbon reductants in their production with renewable alternatives. The plant at Bakki emits about 150,000 tonnes of carbon dioxide annually due to the nature of the chemical reaction that reduces quartzite (SiO2 ) with a carbon reductant to produce silicon metal. Catching and utilizing the emitted renewable carbon to produce green methanol would improve the carbon footprint of ships and industry utilizing such fuel and on top improve the carbon footprint of PCC’s silicon metal plant beyond carbon neutrality. Furthermore, the nature of silicon metals is such that without it, we would neither see the current stellar performance of solar power in the European Union, nor innovative solutions such as next generation battery anodes, which are key to higher capacities.

Peter Wenzel, CEO PCC SE:

“We are ready to take the next step at PCC BakkiSilicon; capture carbon emissions from our production and utilise for the energy transition. Our operations are already on track for carbon neutrality, but the production of green methanol, which can be used as maritime fuel, would certainly be a milestone.”

Hörður Arnarson, CEO Landsvirkjun:

“We at Landsvirkjun welcome the opportunity to collaborate on a green solution with a good customer. The energy transition is urgent, especially in the fleet. If we can use our renewable electricity to produce green methanol at PCC BakkiSilicon, we are one step closer to a green future.”

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye